SCHEMBL4891536

SCHEMBL4891536

Cc1cn2cc(Br)cc(N)c2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.41
APP P05067 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
PIK3CG P48736 1/20 0.34
ALDH1A1 P00352 2/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 2/20 0.33
ADORA2A P29274 2/20 0.33
HTT P42858 1/20 0.33
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
KDM4E B2RXH2 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
MEN1 O00255 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
ADORA1 P30542 1/20 0.32
UHRF1 Q96T88 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4886193 0.81 RXFP1 (0.44) RXFP1APPL3MBTL1ALDH1A1HPGD
SCHEMBL6355229 0.81 GRM5 (0.37) APPALDH1A1HPGDHSD17B10ADORA2A
SCHEMBL23571661 0.81 RXFP1 (0.60) RXFP1APPL3MBTL1HTTNPC1
Bromide SCHEMBL30359290 0.79 RXFP1 (0.58) RXFP1APPL3MBTL1HTTNPSR1
SCHEMBL15068755 0.78 RXFP1 (0.41) RXFP1APPL3MBTL1HTTNPSR1
SCHEMBL31210532 0.78 RXFP1 (0.45) RXFP1APPL3MBTL1ALDH1A1HPGD
SCHEMBL23293908 0.78 RXFP1 (0.41) RXFP1APPL3MBTL1ALDH1A1HTT
SCHEMBL24387034 0.78 APP (0.52) RXFP1APPL3MBTL1HTTNPC1
Bromide SCHEMBL30426544 0.76 RXFP1 (0.41) RXFP1APPL3MBTL1HTTNPSR1
Hydrochloric Acid SCHEMBL31210671 0.76 RXFP1 (0.38) RXFP1APPL3MBTL1PIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024231852-A1 SUBSTITUTED BIPHENYL COMPOUNDS AS CBL-B INHIBITORS GLENMARK PHARMACEUTICALS LTD (IN) 2024-11-14 WO disclosed
WO-2024182788-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2024-09-06 WO disclosed
US-20080255358-A1 Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases GLAXO GROUP LIMITED (GB) 2008-10-16 US disclosed
US-20080255358-A1 Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases GLAXO GROUP LIMITED (GB) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255358-A1 Derivatives of Imidazo [1,2-A] Pyridine Useful as Medicaments For Treating Gastrointestinal Diseases ALPI, PYGL, PPIP5K2 RXFP1 2831/4885APP 4671/4885L3MBTL1 4696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.